Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Checkpoint Therapeutics Inc

CKPT
Current price
3.29 USD +0.03 USD (+0.92%)
Last closed 3.25 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 64 935 260 USD
Yield for 12 month -11.56 %
Week
Month
Year
CKPT
21.11.2021 - 28.11.2021

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 95 Sawyer Road, Waltham, MA, United States, 02453

Analytics

WallStreet Target Price

24.25 USD

P/E ratio

Dividend Yield

Current Year

+192 000 USD

Last Year

+268 000 USD

Current Quarter

+31 000 USD

Last Quarter

+31 000 USD

Current Year

+192 000 USD

Last Year

+268 000 USD

Current Quarter

+31 000 USD

Last Quarter

+31 000 USD

Key Figures CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM -24841.94 %
PE Ratio
Return On Assets TTM -307.4 %
PEG Ratio
Return On Equity TTM -1220.38 %
Wall Street Target Price 24.25 USD
Revenue TTM 171 000 USD
Book Value -0.85 USD
Revenue Per Share TTM 0.008 USD
Dividend Share
Quarterly Revenue Growth YOY -35.4 %
Dividend Yield
Gross Profit TTM -48 185 000 USD
Earnings Share -4.38 USD
Diluted Eps TTM -4.38 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CKPT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 06.12.2022
Dividend Date

Stock Valuation CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 363.8527
Price Sales TTM 379.7384
Enterprise Value EBITDA -1.0613
Price Book MRQ 8.5555

Financials CKPT

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CKPT

For 52 weeks

1.3 USD 8.15 USD
50 Day MA 1.93 USD
Shares Short Prior Month 2 388 572
200 Day MA 2.65 USD
Short Ratio 9.12
Shares Short 2 650 518
Short Percent 12.85 %